Antiviral Drugs and Biologics Targeting HIV: Drug Resistance to Newer Treatment and Pre-Exposure Prophylaxis (PrEP) Options
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 64
Special Issue Editor
Interests: HIV-1 transmission; HIV drug resistance; HIV phylogenetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) are the mainstay of treatment and prevention measures for HIV/AIDS pandemic control. The expanded global access to ART has resulted in an exponential rise in acquired and transmitted HIV drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs), threatening the clinical benefits of ART in long-term HIV management. Recent ART and PrEP options have shifted to integrase strand transfer (INSTI)-based regimens that show higher potency and genetic barriers to resistance. The simplification to two-drug regimens and long-acting injectable formulations may result in a newly emergent resistance. This Special Issue welcomes articles that describe the potency, durability and pharmacokinetics of newer ART and PrEP options for virological suppression and as barriers to resistance.
Characterization of the genotypic, phenotypic, and phylogenetic features of emergent resistance species may provide a more nuanced understanding of the virologic potency and pharmacofragility of streamlined and long-acting regimens.
Prof. Dr. Bluma G. Brenner
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV
- antiretroviral therapy (ART)
- pre-exposure prophylaxis (PrEP)
- antiviral drugs
- drug resistance
